Modular housing company Eco Buildings Group (LON: ECOB) has expanded its geographical reach and the computerisation of the production process. The share price improved 24.2% to 10.25p.
Gunsynd (LON: GUN) says assay results at the Bear Twit project in Canada and they confirm high-grade lead, zinc and siler mineralisation. There are also elevated concentrations of gallium, germanium and copper. The project will move towards a drill-ready stage. The share price rose 11.9% to 0.165p.
Shuka Minerals (LON: SKA) says the loan from Gathoni Muchai Investments has been further delayed, but funds could be cleared next week. This will enable the $1.35m payment for Leopard Exploration and Mining. The share price is one-fifth higher at 6p.
Iodine producer Iofina (LON: IOF) produced 215.8 metric tonnes of crystalline iodine from eight plants. That is a 32% increase. Production started at IO#11 in July. Production is in line with guidance. Foundation wok on IO#12 could start before the end of the year. The share price increased 7.61% to 24.75p.
FALLERS
Premier African Minerals (LON: PREM) is seeking further disapplication of the pre-emption provision for share issues to make it easier to raise the cash it requires. A total of $6.3m is required to settle debts and fund phase 5 of pre-production readiness. This follows the share consolidation earlier this week and the share price declined 14.7% to 0.145p.
Data analysis software provider Cirata (LON: CRTA) has data integration bookings of $3.4m in the first nine months of 2025, although there was a slowdown in bookings in the third quarter. So far, $2.5m has been received for the sale of the DevOps assets with a further $1m expected in December. Annualised costs are $12-$13m. Third quarter cash outflow was $800,000 with cash of $5.4m at the end of September. The share price slipped 10.9% to 18.85p.
Pulsar Helium Inc (LON: PLSR) has filed a preliminary short form base shelf prospectus, which will enable the issue of securities to raise cash up to $50m over a 25-month period. There is no immediate plan to raise money. The share price fell 8.04% to 51.5p.
Pre-clinical antibody supplier Fusion Antibodies (LON: FAB) generated interim revenues of £838,000, down from £1.2m in the first half of last year. Gross margin improved from 22% to 30%. Cash was £251,000 at the end of September 2025. Management is still confident that is has sufficient cash until 2027. The share price is 5.66% lower at 12.5p.
Regenerative medical devices developer Tissue Regenix (LON: TRX) is restating 2024 EBITDA from $1.9m to a loss of $1m. This is due to changes in inventory and cost of sales. It also means that interim positive EBITDA of $200,000 has become a $2.3m loss. There is cash of $1.1m at the end of June 2025 and headroom of debt of $5.6m. Chief executive Daniel Lee is leaving, and Kirsten Lund has been reappointed as finance director. There is a $2m plus cost reduction. The share price slid 5.56% to 8.5p.
Semiconductors designer EnSilica (LON: ENSI) has been hit by a contract delay and a cybersecurity incident at an automotive client that slowed orders. That means that full year EBITDA of £300,000 is expected, compared with £500,000 previously forecast. That is before a £1.6m bad debt provision relating to the contract delay. That contract with SIAE Microelectronics is on hold because of the client’s lack of cash and EU funding may be issued in 2026. The 2026 EBITDA guidance has been reduced to £3.5m-£4.5m. The share price dipped 4.4% to 43.5p.
Ex-dividends
Animalcare (LON: ANC) is paying an interim dividend of 2.2p/share and the share price declined 3p to 228p.
Next 15 Group (LON: NFG) is paying an interim dividend of 4.75p/share and the share price fell 12.25p to 364.75p.